Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma-Reference-Cited by-同舟云学术

Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma

Published:2023-07-13 Issue:12 Volume:108 Page:3502-3505
ISSN:1592-8721
Container-title:Haematologica
language:
Short-container-title:haematol

Author:

Liberatore Carmine,Perini Tommaso,Passeri Cecilia,Ferla Valeria,Fioritoni Francesca,Girlando Virginia,Iuliani Ornella,Orsini Alessia,Montanaro Guido,Farina Francesca,Di Nicola Alessandro,Nitti Rosamaria,Pulini Stefano,Mastaglio Sara,Santarone Stella,Coppola Milena,Marktel Sarah,Accorsi Patrizia,Ciceri Fabio,Marcatti Magda,Di Ianni Mauro

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Reference15 articles.

1. Dimopoulos MA, Moreau P, Terpos E. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(3):309-322.

2. Moreau P, Attal M, Hulin C. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10192):29-38.

3. Hulin C, Offner F, Moreau P. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study. Haematologica. 2021; 106(8):2257-2260.

4. Lemonakis K, Tätting L, Lisak M. Impact of daratumumabbased induction on stem cell collection parameters in Swedish myeloma patients. Haematologica. 2023; 108(2):610-614.

5. Eleutherakis Papaiakovou E, Terpos E, Kanellias N. Impact of daratumumab-containing induction on stem cell mobilization and collection, engraftment and hospitalization parameters among multiple myeloma patients undergoing autologous stem cell transplantation. Blood. 2021; 138(Suppl 1):S3886.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review;Pharmaceuticals;2024-07-15

2. Anti-CD38 monoclonal antibody impairs CD34+mobilization and affects clonogenic potential in multiple myeloma patients;BLOOD TRANSFUS-ITALY;2024

3. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single‐center experience;Cancer Medicine;2024-06

4. Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analy;Mediterranean Journal of Hematology and Infectious Diseases;2024-04-30

5. Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma;Frontiers in Hematology;2024-04-26